Abstract:Background: Osteoprotegerin was implicated in vascular injury and inflammatory responses, but its prognostic value in ischemic stroke remained unclear. We aimed to prospectively investigate the association between plasma osteoprotegerin and ischemic stroke prognosis combined with a Mendelian randomization analysis. Methods: Our prospective study follows the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) reporting guideline. We measured baseline plasma osteoprotegerin levels for 3490 ischemic stroke patients recruited between August 2009 and May 2013 in 26 hospitals across China. The primary outcome was a composite outcome of death and major disability at 3 months after ischemic stroke. Results: After adjustment for age, sex, admission National Institutes of Health Stroke Scale score, and other important covariates, elevated osteoprotegerin levels were associated with increased risks of primary outcome (odds ratio, 1.40 [95% CI, 1.05-1.88]), death (hazard ratio, 2.05 [95% CI, 1.04-4.08]), and composite outcome of death and vascular events (hazard ratio, 2.00 [95% CI, 1.15-3.48]) when 2 extreme quartiles were compared. Each 1-SD higher log-osteoprotegerin was associated with a 18% (95% CI, 6%-32%) increased risk of primary outcome, 69% (95% CI, 31%-118%) increased risk of death, and 53% (95% CI, 24%-89%) increased risk of composite outcome of death and vascular events, respectively. Multiple-adjusted spline regression model showed a linear association of osteoprotegerin with primary outcome (P for linearity <0.001). Adding osteoprotegerin to conventional risk factors did not significantly improve discriminatory power (C statistics, 0.817 versus 0.818; P=0.232) but did slightly improve the risk reclassification of primary outcome (net reclassification improvement: 13.68%, P<0.001; integrated discrimination improvement: 0.23%, P=0.039). In Mendelian randomization analysis, genetically determined high plasma osteoprotegerin was associated with increased risk of primary outcome (odds ratio, 5.74 [95% CI, 1.12-29.44]; P=0.036). Conclusions: Elevated plasma osteoprotegerin was associated with poor prognosis of ischemic stroke, and genetically determined high plasma osteoprotegerin was associated with an increased risk of primary outcome in Mendelian randomization analysis. Registration: URL: https://www. Clinicaltrials: gov; Unique identifier: NCT01840072.

Impact of Serum Omentin-1 Levels on Functional Prognosis in Nondiabetic Patients with Ischemic Stroke.

Dynamic Changes and Prognostic Value of Gut Microbiota-Dependent Trimethylamine-N-Oxide in Acute Ischemic Stroke.

Clinical relevance of serum omentin‐1 levels as a biomarker of prognosis in patients with acute cerebral infarction

Omentin-1: Protective impact on ischemic stroke via ameliorating atherosclerosis

Low Serum Superoxide Dismutase is Associated with a High Risk of Cognitive Impairment after Mild Acute Ischemic Stroke

Adipose tissue specific insulin resistance and prognosis of nondiabetic patients with ischemic stroke

Serum Prealbumin Levels and Risks of Adverse Clinical Outcomes after Ischemic Stroke

Serum heme oxygenase‐1 level predicts clinical outcome after acute ischemic stroke

Serum Heme Oxygenase-1 Predicts Clinical Outcome and Hemorrhagic Transformation after Acute Ischemic Stroke

Omentin associates with serum metabolite profiles indicating lower diabetes risk: KORA F4 Study

Correlation Between Adiponectin Level and Ischemic Stroke Risk and Patient Prognosis: An Updated Meta-Analysis

Osteoprotegerin and Ischemic Stroke Prognosis: A Prospective Multicenter Study and Mendelian Randomization Analysis

Association of circulating omentin-1 level with arterial stiffness and carotid plaque in type 2 diabetes

Association of high serum β2-microglobulin levels with poor functional outcomes in patients with acute ischemic stroke: A cohort study

Prognostic significance of plasma visfatin levels in patients with ischemic stroke.

Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults

Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies

Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke

The Association of Systemic Inflammatory Response Index and Neutrophil-to-High-Density Lipoprotein Ratio Mediated by Fasting Blood Glucose with 90-Day Prognosis in Acute Ischemic Stroke Patients

Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies

What is the impact of acute endocrine and metabolic alterations on long-term ischemic stroke prognosis: a prospective study